Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

Malnutrition in Hepatorenal Syndrome Associated with Liver Cirrhosis

Shobha[1], Madhavi Reddy[2]*, Prabhakar[3], Nitin rao[4]

[1] MSc (FSN), PG (CCN), PG (DDM), Ph.D. Scholar, Department of Clinical Nutrition and Dietetics, Sri Devaraj Urs Academy of Higher Education and Research Kolar, Tamaka-563103, India.

[2] MSc, Ph.D. Professor and HOD & Faculty of Clinical Nutrition, Department of Clinical Nutrition and Dietetics, Sri Devaraj Urs Academy of Higher Education and Research Kolar, Tamaka-563103, India.

[3] MBBS, MD, Professor and Physician, Department of General Medical, Sri Devaraj Urs Academy of Higher Education and Research, Kolar. Tamaka-563103, India.

[4] MBBS, FTS (Australia), FACS (USA), Professor and Gastroenterologist, Department of Surgical Gastroenterology, M S Ramaiah hospitals, Banglore - 560054, India.

Corresponding Author*:

Dr. Madhavi Reddy, Professor. Department of Clinical Nutrition and Dietetics, Sri Devaraj Urs Academy of Higher Education and Research Centre. Kolar, Karnataka, India.

(Received: 16 September 2024 Revised: 11 November 2024 Accepted: 11 January 2025)

KEYWORDS

Hepatorenal syndrome, Cirrhosis, Malnutrition, Acute Renal Failure and Decompensated Cirrhosis

ABSTRACT:

Malnutrition is a prevalent and significant comorbidity among individuals diagnosed with liver cirrhosis, often exacerbated by the onset of hepatorenal syndrome. The objective of this narrative literature review is to explore the complex relationship between malnutrition, liver cirrhosis, and hepatorenal syndrome, highlighting the factors that contribute to malnutrition, its effects on the pathophysiology of hepatorenal syndrome, and the implications for clinical practice. The review highlights the high prevalence of malnutrition among patients with liver cirrhosis, particularly those who develop hepatorenal syndrome. It identifies key characteristics of malnutrition in this population, including sarcopenia, depleted protein stores, and micronutrient deficiencies. These nutritional deficits significantly impair immune function, increase susceptibility to infections, and adversely affect both renal and liver function. The paper also notes that the inflammatory response associated with cirrhosis and renal dysfunction exacerbates catabolic processes, worsening nutritional deficiencies and underscoring the need for targeted nutritional interventions in this vulnerable patient group. Additionally, malnutrition adversely affects the efficacy of therapeutic interventions and increases the risk of complications, including infections and elevated mortality rates. Emerging evidence suggests that while implementing targeted nutritional support in the context of hepatorenal syndrome presents challenges, it is essential for improving patient outcomes. Therefore, the early identification of malnutrition and the proactive application of nutritional strategies are critical for enhancing the management of renal impairment in patients with liver cirrhosis.

1. Introduction

Cirrhosis leads not only to renal changes but also to nutritional deficiencies, profoundly affecting patient outcomes. Hepatorenal syndrome (HRS) is a complex condition characterized by renal dysfunction in individuals with advanced liver disease, often resulting in significant morbidity and mortality [1]. The incidence of HRS among patients with cirrhosis ranges from 0.7% to 17.5% and is predicted to impact up to 10% of cirrhosis patients, the stated prevalence ranges between 7 and 45% [2,3]. It affects more males than women and is more prevalent in patients with severe stages of cirrhosis [4]. It is also linked to the development of ascites and is more prevalent in hospitalized or critical care unit patients [5]

The specific cause of HRS is unknown; however, it is thought to be complex. HRS is categorized into two clinical forms: HRS type 1 and HRS type 2. HRS1 is more severe and progresses more quickly than the others renal diseases [6,7]. Hepatocellular dysfunction, intrahepatic and systemic inflammation, portal hypertension, and changes in the

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

renin-angiotensin-aldosterone system are among the possible causes. HRS is diagnosed based on certain clinical criteria, such as ascites, a serum creatinine level greater than 2 mg/dL, and the lack of other causes of acute renal damage [8]. Specific test abnormalities, including high serum bilirubin levels (> 2 mg/dL), serum creatinine levels (> 2 mg/dL), and urine salt concentrations (< 10 mmol/L), further support the diagnosis. The diagnosis of HRS requires the exclusion of other potential causes of renal failure, as well as the identification of specific clinical and laboratory indicators, including elevated serum creatinine levels and decreased urine output [9,10]. Factors such as advanced age, the presence of ascites, and bacterial infections are associated with an increased risk of developing HRS. HRS has a terrible prognosis, with fatality rates reaching up to 80%. Infection is the leading cause of mortality, followed by cardiovascular and chronic liver failure [11].

The relationship between hepatic impairment and renal failure underscores the importance of understanding the nutritional needs of affected patients. Proper nutrition is essential for this population, as it can influence the progression of both liver and kidney function, enhance overall health, and improve quality of life [12]. Current medical management options for HRS are albumin infusions, diuretics, and renal replacement therapy. Despite a growing recognition of the critical role of nutritional management in the treatment of HRS, specific dietary guidelines remain insufficiently explored and poorly defined in the current literature. Existing recommendations generally rely on broad nutritional guidelines applicable to liver disease and renal failure; however, they lack tailored strategies specifically designed for individuals with HRS [13,14]

The nutritional management of patients with Hepatorenal Syndrome (HRS) is critically important, primarily due to the high prevalence of malnutrition within this population. Although precise statistics on malnutrition specifically among HRS patients are limited, research examining patients with liver disease more broadly indicates that over 50% of this cohort is malnourished [15]. The validity of the criteria used to define malnutrition is a topic of debate, particularly as individuals classified as well-nourished often demonstrate significantly poorer health outcomes compared to healthy controls. Furthermore, malnutrition is believed to have a substantial impact on clinical outcomes, as it is associated with an increased risk of adverse effects and mortality among patients with liver disease, including those with HRS. Nutritional interventions in this demographic have been shown to enhance survival rates and improve various health outcomes [16].

Given that HRS demonstrates a unique pathophysiological profile, it is essential to implement customized nutritional interventions that are specific to the individual rather than applying a one-size-fits-all approach. Although a limited number of studies have attempted to propose dietary guidelines for HRS, these studies often recommend various foods traditionally regarded as beneficial for liver or kidney conditions. However, the rationale supporting the claimed benefits of these foods is frequently based on insufficient evidence derived from inadequately conducted research [17].

Consequently, it is essential to develop a comprehensive understanding of the influence of nutrition on the etiology of Hepatorenal Syndrome, its correlation with disease progression, and the role of nutritional interventions in the management of this condition. The objective of this literature review is to synthesize the current body of knowledge regarding the relationship between dietary factors and HRS, to examine the existing evidence, and to pinpoint areas that warrant further investigation.

Prevalence and Risk Factors of Malnutrition in HRS

The research consistently shows a significant frequency of malnutrition in HRS patients. Several studies have found that a considerable number of HRS patients suffer from protein-energy malnutrition, which is associated with low albumin levels, reduced muscle mass, and compromised immunological function. This malnutrition is caused by a combination of causes, including decreased oral intake owing to ascites, anorexia, and nausea, delayed nutritional absorption due to gastrointestinal dysfunction, and increased metabolic load associated with the illness [18-20]. Research indicates that the prevalence of malnutrition in this population ranges from 20% to 80%, depending on the specific group studied and the assessment methodologies employed [21,22]. The etiology of malnutrition in individuals with cirrhosis associated HRS is multifactorial, involving altered metabolic

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

processes, inadequate nutritional intake, and increased energy expenditure. Furthermore, the presence of comorbid conditions in cirrhosis such as portal hypertension, gastrointestinal bleeding, exacerbates malnutrition through both inflammatory and metabolic pathways [23,24].

1. Relationship Between Malnutrition and HRS

Impact of Malnutrition on HRS

Malnutrition significantly impacts the progression and outcomes of hepatorenal syndrome. In cirrhosis patients with HRS, malnutrition is associated with increased mortality, reduced quality of life, and higher readmission rates [25]. Individuals with hepatorenal syndrome often exhibit low nutritional status, creating a vicious cycle of deteriorating liver disease and declining renal function. Malnutrition can exacerbate renal impairment by disrupting immune function, increasing oxidative stress, and worsening metabolic disturbances [26]. Several studies indicate that malnutrition in this population correlates with prolonged hospital stays, elevated healthcare costs, and challenges in adhering to treatment regimens. According to the existing research, malnutrition affects the severity and prognosis of HRS. Malnourished HRS patients are more likely to suffer complications such as infections, spontaneous bacterial peritonitis (SBP), and hepatic encephalopathy. Furthermore, malnutrition is linked to a worse response to therapy and an increase in mortality [27-29]. Nutritional support may be essential for improving outcomes in individuals suffering from HRS and malnutrition.

Nutritional Pathophysiology

The mechanisms contributing to malnutrition in individuals with liver cirrhosis associated HRS are intricate. The liver plays a vital role in protein synthesis and metabolism; therefore, its impairment leads to a state of protein-energy malnutrition, hypoalbuminemia and hypoproteinemia. As liver function continues to decline, primarily due to diminished energy reserves, the ability to perform gluconeogenesis becomes compromised. This leads to hypoglycemia and, ultimately, a decrease in caloric intake, which is further exacerbated by a reduced appetite associated with ascites [30]. Additionally, malabsorption due to liver failure, heightened catabolic activity, and hormonal imbalances further exacerbate malnutrition in these patients [31].

Metabolic Alterations

It is estimated that 60-90% of cirrhotic patients diagnosed with HRS have severe malnutrition. While the exact impact of this nutritional shortage on metabolic systems is unknown, it is understood that such deficiencies have negative consequences. Furthermore, it is assumed that the protein being digested is transformed to energy by processes that release substandard amino acids into the bloodstream. Regardless of the conditions within the hydrolytic cells of the digestive system, protein breakdown is not fulfilling its intended purpose. This is most likely due to a deficiency of essential amino acids, which are necessary for protein synthesis, as well as a lack of enzymes that enhance the efficiency of the metabolic pathways responsible for generating the energy required by all cells in the body [32,33].

Insulin resistance and impaired gluconeogenesis are key features of altered glucose metabolism, leading to prolonged hypoglycemia and an unstable metabolic state. These underlying metabolic abnormalities also affect lipid metabolism by increasing lipolysis and decreasing lipogenesis [34,35]. Additionally, oxidative stress and systemic inflammation exacerbate metabolic dysfunction and malnutrition. Collectively, these factors significantly influence patients' responses to treatment and, more importantly, their prognoses.

2. Nutritional Assessment Methods

Evaluating the nutritional status of patients with Hepatorenal Syndrome presents significant challenges, necessitating a novel combination of traditional and modern diagnostic approaches to achieve a comprehensive understanding. In this context, conventional anthropometric markers such as body mass index (BMI), mid-arm circumference, and triceps skinfold thickness are often unreliable [36]. This inaccuracy arises from the difficulties in accurately correlating these measurements with muscle mass, particularly in patients exhibiting fluid retention. Historically, methods for assessing nutritional status relied on a combination of inadequate proxies and subjective estimates. Proper nutritional evaluation is critical in detecting malnutrition in cirrhosis and HRS patients. Various techniques, such as the Subjective

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

Global Assessment (SGA), the Malnutrition Universal Screening Tool (MUST), and the Royal Free Hospital Nutrition Tool (RFH-NPT), can be used to assess nutritional status [37]. These techniques offer a more holistic framework by gathering extensive data and presenting it in a manner that effectively conveys the complete nutritional profile.

Biochemical indicators are essential for assessing nutritional status. However, it is crucial to recognize that these markers can be misleading, as they often indicate liver disease rather than dietary deficiencies. Traditionally, it has been believed that because the liver plays a vital role in metabolism, any signal derived from hepatocyte metabolism serves as a reliable indicator of liver function. Consequently, serum albumin, prealbumin, and transferrin, these proteins synthesized in the liver are commonly used as indicators of malnutrition [38]. Nonetheless, these markers primarily reflect liver function and the operational state of hepatocytes, rather than providing a comprehensive view of an individual's nutritional status. Conversely, specific nutritional assessments that do not depend on hepatic function can provide valuable insights into an individual's nutritional status. For example, handgrip strength has been identified as a reliable indicator of nutritional health, as muscle integrity is closely linked to dietary intake.

Using various assessment techniques, such as body composition measurement through bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA), provides a significantly more comprehensive understanding of a patient's nutritional and metabolic condition than relying solely on a few traditional dietary evaluation methods [39]. This is particularly relevant for individuals with severe metabolic disorders, such as hepatorenal syndrome, where liver or kidney dysfunction renders most standard approaches ineffective in accurately assessing a patient's true nutritional status. Nevertheless, even in such challenging circumstances, utilizing these assessment tools to their fullest potential and interpreting the results in conjunction with established nutritional knowledge can lead to genuinely lifesaving nutritional interventions.

3. Management Strategies for Malnutrition in HRS

Given the complicated interaction between liver and kidney function, dietary management is critical in the overall care of HRS patients. According to the American Association for the Study of Liver Diseases (AASLD), proper nutritional support is critical for maintaining liver function and supporting healing [40].

Macronutrient Management

Nutritional therapy should be tailored to the individual requirements of patients with liver cirrhosis and HRS. Increased caloric intake by oral supplements is recommended, as is a high protein diet, and enteral nutrition may be administered in situations of severe malnutrition [41]. Dietary changes in HRS patients often include protein restriction, particularly during acute episodes, to reduce the formation of ammonia and other nitrogenous waste products that might worsen hepatic encephalopathy [42]. Total protein restriction, on the other hand, might result in malnutrition, which impairs immunological function and may have a negative impact on patient outcomes. Oral branched-chain amino acids have also been investigated for their potential advantages in enhancing nutritional status and liver function [43]. Recent research suggests that a balanced strategy, emphasizing high-quality protein sources and regulating protein consumption based on the severity of hepatic encephalopathy, may significantly improve nutritional status while not dramatically raising the risk of neurological problems [44]. But studies relating to HRS and protein recommendations are limited.

Hepatorenal syndrome can be effectively managed through the appropriate implementation of macronutrient management strategies. This necessitates meticulous tracking of carbohydrate, lipid, and, most importantly, protein intake. Current guidelines recommend that individuals with HRS consume between 1.2 and 1.5 grams of protein per kilogram of body weight each day. This protein intake significantly exceeds the Recommended Dietary Allowance (RDA) of 0.8 grams per kilogram. While the shift from the RDA to the recommended intake for HRS may seem gradual and logical, a comprehensive review of clinical studies reveals a significant lack of empirical evidence to substantiate these dietary recommendations [45].

Carbohydrate consumption should be carefully regulated, with guidelines suggesting that complex

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

carbohydrates should comprise 45-50% of total daily caloric intake. This approach is essential for ensuring that cellular processes receive adequate energy and substrates. Individuals with insulin resistance, a prevalent condition associated with HRS, must meticulously manage their carbohydrate intake to maintain strict control over blood glucose levels [46]. Inadequate provision of energy and substrates for cellular functions can lead to more significant complications, such as diabetes, which can extend beyond the scope of HRS.

Fats should comprise 25-30% of total calorie intake, emphasizing medium-chain triglycerides (MCTs) and essential fatty acids. MCTs represent a unique class of lipids that are absorbed and metabolized differently from other types of fats [47]. Unlike other fats, they do not require bile for intestinal absorption; instead, upon entering the gastrointestinal tract, they are transported directly into the portal vein and subsequently to the liver, where they are primarily converted into energy in the form of ketones. Due to their distinct absorption and metabolic pathways, MCTs are unlikely to contribute to or exacerbate the condition of fatty liver [48].

Micronutrient Supplementation

Patients with hepatorenal syndrome often experience micronutrient deficiencies, which may arise from inadequate food intake, malabsorption issues, and suboptimal metabolic adaptation to liver disease and its consequences. Due to the prevalence of vitamin deficiencies in cirrhosis population, the primary objective is to identify the same specific vitamins for HRS and to provide supplementation until one confirms that these patients have achieved adequate levels of these essential nutrients. Usually B-complex vitamins, particularly thiamine and folate, are crucial for preventing neurological issues and supporting normal metabolic functions even in HRS patients. A daily thiamine supplementation of 100 mg is typically recommended, while the necessary folate intake ranges from 400 to 800 mcg. Additionally, mineral supplementation is vital, with a focus on zinc, magnesium, and selenium. Zinc deficiency is prevalent among individuals with HRS and can be effectively addressed by administering 20 to 40 mg of elemental zinc daily [49].

Iron supplementation should be approached with caution, as excessive iron intake can compromise liver function. Monitoring serum ferritin levels is essential for guiding treatment strategies. Additionally, individuals with liver disease may benefit from selenium supplementation at a daily dosage of 55-70 mcg, which can support immune function and help maintain the liver's critical antioxidant roles [50]. Dietary adjustments, such as limiting salt and fluid consumption, are critical in treating fluid retention and ascites. Regular assessment of serum levels should be incorporated into the treatment plan for these two nutrients. This approach is vital not only for determining optimal dosages and types of supplements but also for safeguarding patient health by preventing both deficiencies and toxicities. Furthermore, ongoing monitoring can help ensure that the therapeutic benefits of vitamin supplementation are maximized.

4. Renal Function

The effect of dietary assistance on renal function has been studied using blood creatinine levels, estimated glomerular filtration rate (eGFR), and the necessity for renal replacement therapy (RRT) [51]. While some research demonstrate that dietary therapies enhance renal function, the outcomes are not consistently statistically significant across studies. More research with bigger sample numbers and defined dietary regimens is required to definitely determine the influence of nutrition on particular renal function markers.

5. Role of Pharmacotherapy

Pharmacotherapy might possibly help manage malnutrition in HRS. Medications that improve appetite, such as Megestrol acetate, can help with nutritional recovery, although their effectiveness is unpredictable [52]. Furthermore, probiotics have been studied for their ability to promote gut health and absorption, hence improving nutritional status [53].

6. Liver Transplantation

Cirrhosis and its consequences, especially HRS, continue to be treated definitively by liver transplants. Malnutrition prior to transplantation may have a deleterious influence on surgical results, although it has been found to improve dramatically after

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

transplantation with sufficient nutritional assistance. As a result, treating malnutrition before to transplantation can improve the patient's overall prognosis and recovery [54].

7. Clinical Implementation and Outcomes

The role of diet in the management of hepatorenal syndrome is being explored within clinical contexts, with preliminary findings indicating potential benefits for patients. Current medical treatment strategies for HRS seem to be yielding positive outcomes, as evidenced by emerging data. The available data repeatedly highlights the strong link between malnutrition and negative outcomes in HRS. The high frequency of malnutrition in HRS patients, particularly protein-energy malnutrition, emphasizes the importance of early detection and care of this critical feature of illness. The level of significance found in research relating low nutritional status to a poor prognosis highlights the need for nutritional assistance in improving the quality of care. However, the variability of research designs, treatments, and outcomes described in the literature warrants a careful interpretation of findings. The conflicting outcomes from RCTs studying particular dietary therapies show the need for more research to determine the most effective interventions and their suitable implementation in various populations of HRS patients.

According to some research, their survival rates are around 30% higher than those of identical patients who do not receive these two important interventions. The positive benefits of albumin treatment in this regard appear to be amplified in particular circumstances. Notably, one study indicates that the implementation of structured exercise programs, in conjunction with specific nutritional supplements such as the amino acid leucine, may significantly improve both survival rates and quality of life for patients with liver cirrhosis who are affected by HRS.

Despite the underlying difficulties of HRS, the emergence of a newer and more complete set of clinical criteria has greatly simplified diagnosis. The use of evidence-based medicine has significantly improved the implementation of these procedures. Despite these developments, people with HRS continue to underutilize recognized medicinal and dietary therapy. This field of study is evolving, and the function of dietary therapies appears to be becoming increasingly important to the overall management of patients in HRS. A group of professionals provides the following in a persuasive explanation of this area: Nutritional treatment is simply a strategy for influencing the patient's metabolism and pathophysiology; it is closely linked to medicine. Nonetheless, despite its well-recognized relevance, nutritional treatment has typically had few experts. However, it has the potential to be one of the most effective treatments in medicine.

Several studies have emphasized the necessity of dietary assistance in treating HRS patients. While the form and efficacy of nutritional treatments vary, the evidence generally points to the benefits of maintaining appropriate protein consumption, regulating energy balance, and treating micronutrient deficiencies. This literature evaluation has attempted a detailed overview, highlighted current knowledge gaps, and suggested future research options. Future research might focus on determining the optimal protein and energy requirements for HRS patients, the long-term impact of various dietary treatments on renal function and survival, a cost-effectiveness study of several dietary regimens in HRS treatment and how certain micronutrients improve HRS results.

By knowing the existing data supporting the advantages of dietary therapies in HRS, doctors may create more effective and personalized treatment strategies to enhance patient outcomes and perhaps lower the high death rate associated with this life-threatening disorder.

8. Challenges, Limitations, and Future Directions

The literature review has inherent constraints in combining data from several research using different approaches. Despite advances in our knowledge of the function of diet in HRS, significant obstacles remain. The diversity of HRS patients, the complexities of addressing their dietary demands, and the scarcity of large-scale RCTs all impede the creation of consistent nutritional guidelines. More investigation is necessary to enhance nutritional requirements therapies, such as evaluating the significance of particular nutrient formulations, examining the impact of alternative delivery systems, and comprehending the interaction between inflammatory responses and nutritional requirements in HRS.

Future study should concentrate on standardizing evaluation techniques for nutritional status in HRS

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

patients, providing uniform data reporting across several investigations. Furthermore, bigger, well-designed RCTs are needed to optimize nutritional therapies based on individual patient features and illness stages. Research into possible biomarkers reflecting nutritional status and their function in predicting HRS outcomes should give useful insights for individualized care.

9. Conclusion

The intricate relationship between malnutrition and hepatorenal syndrome in patients with liver cirrhosis demonstrates the importance of integrated management approaches in this high-risk population. Regular multidisciplinary approach to nutritional assessment, tailored dietary interventions, and appropriate pharmacotherapy can significantly improve outcomes and quality of life. Future research should focus on elucidating the underlying mechanisms linking malnutrition and HRS while developing targeted strategies for prevention and treatment.

Conflict of Interest and Funding: None

Ethical Clearance: Not Applicable

Reference

1. Ginès P., Solà E., Angeli P., Wong F., Nadim M.K., Kamath P.S.,(2018). Hepatorenal syndrome. Nature Reviews Disease Primers. 4(1),23.
2. Singh J., Dahiya D.S., Kichloo A., Singh G., Khoshbin K., Shaka H., (2021) Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018. Annals of Medicine. 53(1), 2018-24.
3. Amin A.A., Alabsawy E.I., Jalan R., Davenport A. (2019). Epidemiology, pathophysiology, and management of hepatorenal syndrome. In Seminars in Nephrology. 39(1), 17-30
4. Davenport A., Sheikh M.F., Lamb E., Agarwal B., Jalan R., (2017). Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?. Kidney international. 92(5), 1058-70.
5. Francoz C., Durand F., Kahn J.A., Genyk Y.S., Nadim M.K., (2019). Hepatorenal syndrome. Clinical Journal of the American Society of Nephrology. 14(5), 774-81.
6. Durand F., Graupera I., Gines P., Olson J.C., Nadim M.K., (2016). Pathogenesis of hepatorenal syndrome: implications for therapy. American Journal of Kidney Diseases. 67(2), 318-28.
7. Bucsics, T., Krones, E. (2017). Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterology report, 5(2), 127–137.
8. Tariq, R., & Singal, A. K. (2020). Management of Hepatorenal Syndrome: A Review. Journal of clinical and translational hepatology, 8(2), 192–199.
9. Fida, S., Khurshid, S. M. S., Mansoor, H. (2020). Frequency of Hepatorenal Syndrome Among Patients With Cirrhosis and Outcome After Treatment. Cureus, 12(8), e10016.
10. Møller, S., Krag, A., Bendtsen, F. (2014). Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. Liver international : official journal of the International Association for the Study of the Liver, 34(8), 1153–1163.
11. McCormick P. A. (2000). Improving prognosis in hepatorenal syndrome. Gut, 47(2), 166–167.
12. Elsebaie, E. M., Abdel-Fattah, A. N., Bakr, N. A., Attalah, K. M., Aweas, A.-H. A. (2023). Principles of Nutritional Management in Patients with Liver Dysfunction—A Narrative Review. Livers, 3(2), 190-218.
13. Arroyo, V., & Colmenero, J. (2003). Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. Journal of hepatology, 38 Suppl 1, S69–S89.
14. Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.), 74(2), 1014–1048.
15. Naik, R., Bali, A., Shaik , B. F., Kata, M., Arora, H., Chandramohan, D., Ramachandran, R.. (2023). Hepatorenal Syndrome. Advances in Renal Diseases and Dialysis, 19–34.
16. Davenport, A., Ahmad, J., Al-Khafaji, A., Kellum, J. A., Genyk, Y. S., Nadim, M. K. (2012). Medical management of hepatorenal syndrome. Nephrology, dialysis, transplantation : official publication of the

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(1), 421-429 | ISSN:2251-6727

European Dialysis and Transplant Association - European Renal Association, 27(1), 34–41.

17. Rendy., Febyan., Wetarini, K. (2021). Clinical Practice of Hepatorenal Syndrome: A Brief Review on Diagnosis and Management. European Journal of Medical and Health Sciences, 3(2), 1–7.
18. Elsebaie, E. M., Abdel-Fattah, A. N., Bakr, N. A., Attalah, K. M., Aweas, A.-H. A. (2023). Principles of Nutritional Management in Patients with Liver Dysfunction—A Narrative Review. Livers, 3(2), 190-218.
19. Kilani Y., Aldiabat M., Alsakarneh S., Puello P.C., Arshad I., Kumar V., Vikash F. (2023). S1418 Clinical Malnutrition Is Associated With Worse Outcomes in Patients With Decompensated Liver Cirrhosis: A 5-Year Population-Based Study. Official journal of the American College of Gastroenterology. 118(10S),S1082-3.
20. Gracia-Sancho, J., Marrone, G., Fernández-Iglesias, A. (2019) Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol. 16, 221–234 .
21. Yves Guigoz., B. Vellas., (2021). Nutritional Assessment in Older Adults: MNA® 25 years of a Screening Tool & a Reference Standard for Care and Research; What Next?, The Journal of nutrition, health and aging, 25(4), 528-583.
22. Cabré, E., Gassull, M. A. (2005). Nutrition in liver disease. Current opinion in clinical nutrition and metabolic care, 8(5), 545–551.
23. Mendez-Guerrero, O., Carranza-Carrasco, A., Chi-Cervera, L. A., Torre, A., Navarro-Alvarez, N. (2024). Optimizing nutrition in hepatic cirrhosis: A comprehensive assessment and care approach. World journal of gastroenterology, 30(10), 1313–1328.
24. Iwasa, M., Iwata, K., Hara, N., Hattori, A., Ishidome, M., Sekoguchi-Fujikawa, N., Mifuji-Moroka, R., Sugimoto, R., Fujita, N., Kobayashi, Y., & Takei, Y. (2013). Nutrition therapy using a multidisciplinary team improves survival rates in patients with liver cirrhosis. Nutrition (Burbank, Los Angeles County, Calif.), 29(11-12), 1418–1421.
25. Dimou, A., & Aytac, E. The impact of nutritional status on outcomes in patients undergoing liver transplantation: A systematic review. *Transplantation Proceedings*. 2023; 55(1), 1-12.
26. Sam, J., & Nguyen, G. C. (2009). Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver international : official journal of the International Association for the Study of the Liver, 29(9), 1396–1402.
27. Heidemann, J., Bartels, C., Berssenbrügge, C., Schmidt, H., & Meister, T. (2015). Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterology research and practice, 2015, 457613.
28. Cárdenas A. (2005). Hepatorenal syndrome: a dreaded complication of end-stage liver disease. The American journal of gastroenterology, 100(2), 460–467.
29. Siddiqui A.T.S., Parkash O., Hashmi S.A., (2021) Malnutrition and liver disease in a developing country. World J Gastroenterol, 27(30): 4985-4998
30. Cheung, K., Lee, S. S., Raman, M. (2012). Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 10(2), 117–125.
31. Terbah, R., Testro, A., Gow, P., Majumdar, A., & Sinclair, M. (2023). Portal Hypertension in Malnutrition and Sarcopenia in Decompensated Cirrhosis-Pathogenesis, Implications and Therapeutic Opportunities. Nutrients, 16(1), 35.
32. Traub, J., Reiss, L., Aliwa, B., & Stadlbauer, V. (2021). Malnutrition in Patients with Liver Cirrhosis. Nutrients, 13(2), 540.
33. Tapper E.B., Parikh N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: Observational study. BMJ. 2018;362:k2817.
34. Clarembeau, F., Bale, G., Lanthier, N. (2020). Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments. Clinical science (London, England : 1979), 134(16), 2117–2135.
35. Matyas, C., Haskó, G., Liaudet, L. Eszter Trojnar., Pal.Pacher. (2021). Interplay of cardiovascular mediators, oxidative stress and inflammation in liver

disease and its complications. Nat Rev Cardiol 18, 117–135 .

36. Molfino, A., Johnson, S., Medici, V. (2017). The Challenges of Nutritional Assessment in Cirrhosis. Current nutrition reports, 6(3), 274–280.
37. Ney, M., Li, S., Vandermeer, B., Gramlich, L., Ismond, K. P., Raman, M., Tandon, P. (2020). Systematic review with meta-analysis: Nutritional screening and assessment tools in cirrhosis. Liver international : official journal of the International Association for the Study of the Liver, 40(3), 664–673.
38. Deorukhkar, D., Sonawale, A., Goyal, A., Sonawale, K. (2023). Deranged Biochemical Markers As Early Predictors for the Development of Hepatorenal Syndrome in Patients With Alcoholic Liver Cirrhosis. Cureus, 15(10), e47927.
39. Saraswat, V. A., Kumar, K. (2022). Untangling the Web of Malnutrition, Sarcopenia, and Frailty in Chronic Liver Disease. Journal of clinical and experimental hepatology, 12(2), 268–271.
40. Pose, E., Piano, S., Juanola, A., Ginès, P. (2024). Hepatorenal Syndrome in Cirrhosis. Gastroenterology, 166(4), 588–604.e1.
41. DiCecco, S. R., Wieners, E. J., Wiesner, R. H., Southorn, P. A., Plevak, D. J., & Krom, R. A. (1989). Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clinic proceedings, 64(1), 95–102.
42. Holm, E., Sedlaczek, O., Grips, E. (1999). Amino acid metabolism in liver disease. Current opinion in clinical nutrition and metabolic care, 2(1), 47–53.
43. Bémeur, C., Butterworth, R. F. (2014). Nutrition in the management of cirrhosis and its neurological complications. Journal of clinical and experimental hepatology, 4(2), 141–150.
44. Gupta, K., Bhurwal, A., Law, C., Ventre, S., Minacapelli, C. D., Kabaria, S., Li, Y., Tait, C., Catalano, C., & Rustgi, V. K. (2021). Acute kidney injury and hepatorenal syndrome in cirrhosis. World journal of gastroenterology, 27(26), 3984–4003.
45. Ambühl P. M. (2011). Protein intake in renal and hepatic disease. International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 81(2-3), 162–172.
46. Elsebaie, E. M., Abdel-Fattah, A. N., Bakr, N. A., Attalah, K. M., & Aweas, A.-H. A. (2023). Principles of Nutritional Management in Patients with Liver Dysfunction—A Narrative Review. Livers, 3(2), 190-218.
47. Sinha, Archana & Prasad, Narayan. (2024). Dietary Management in Patients with Liver Cirrhosis and Renal Failure. Journal of Renal Nutrition and Metabolism. 8. 39-42.
48. Puri, P., Dhiman, R. K., Taneja, S., Tandon, P., Merli, M., Anand, A. C., Arora, A., Acharya, S. K., Benjamin, J., Chawla, Y. K., Dadhich, S., Duseja, A., Eapan, C. E., Goel, A., Kalra, N., Kapoor, D., Kumar, A., Madan, K., Nagral, A., Pandey, G., Wadhawan, M. (2021). Nutrition in Chronic Liver Disease: Consensus Statement of the Indian National Association for Study of the Liver. Journal of clinical and experimental hepatology, 11(1), 97–143.
49. Shah, N. D., Barritt, A. S., 4th (2022). Nutrition as Therapy in Liver Disease. Clinical therapeutics, 44(5), 682–696.
50. Kozeniecki, M., Ludke, R., Kerner, J., Patterson, B. (2020). Micronutrients in Liver Disease: Roles, Risk Factors for Deficiency, and Recommendations for Supplementation. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 35(1), 50–62.
51. Piano, S., Tonon, M., Angeli, P. (2018). Management of ascites and hepatorenal syndrome. Hepatology international, 12(Suppl 1), 122–134.
52. Yang, X., Lei, L., Shi, W., Li, X., Huang, X., Lan, L., Lin, J., Liang, Q., Li, W., Yang, J. (2024). Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials. Frontiers in medicine, 11, 1379333.
53. Dazıroğlu, M. E. Ç., Yıldıran, H. (2023). Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis. Annals of gastroenterology, 36(2), 141–148.
54. Wadei, H. M., Mai, M. L., Ahsan, N., Gonwa, T. A. (2006). Hepatorenal syndrome: pathophysiology and management. Clinical journal of the American Society of Nephrology : CJASN, 1(5), 1066–1079.